SCHEMBL5147000

SCHEMBL5147000

CC(O)Cc1ccc(Br)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
ALDH1A1 P00352 7/20 0.37
GSK3B P49841 2/20 0.34
HPGD P15428 4/20 0.33
DAO P14920 1/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
TSHR P16473 1/20 0.31
KMT2A Q03164 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
RXFP1 Q9HBX9 2/20 0.31
PPARG P37231 2/20 0.31
NCOA2 Q15596 2/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10130574 0.83 KDM4E (0.43) KDM4ETDP1L3MBTL1CES2CES1
SCHEMBL6641492 0.79 KDM4E (0.41) KDM4ETDP1ALDH1A1
SCHEMBL10387818 0.79 KDM4E (0.41) KDM4ETDP1ALDH1A1
SCHEMBL5432901 0.77 PRMT6 (0.47) KDM4EALDH1A1HPGDDAOMAPT
SCHEMBL25362839 0.75 KMT2A (0.42) ALDH1A1GSK3BHPGDDAOHTT
SCHEMBL6682061 0.75 KMT2A (0.42) ALDH1A1GSK3BHPGDDAOHTT
SCHEMBL9071088 0.75 KMT2A (0.42) ALDH1A1GSK3BHPGDDAOHTT
SCHEMBL5174394 0.75 TP53 (0.43) KDM4ETDP1L3MBTL1CES2CES1
SCHEMBL14340880 0.74 L3MBTL1 (0.40) KDM4ETDP1L3MBTL1CES2CES1
SCHEMBL14340878 0.73 CYP2C19 (0.48) KDM4ETDP1L3MBTL1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562588-A4 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO INC (US) 2007-10-31 EP disclosed
EP-1592419-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION Merck Frosst Canada & Co. (CA) 2005-11-09 EP disclosed
EP-1562588-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS Merck & Co., Inc. (US) 2005-08-17 EP disclosed
EP-1436290-A1 ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR Merck Frosst Canada & Co. (CA) 2004-07-14 EP disclosed
WO-2004047836-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION MERCK FROSST CANADA & CO. (CA) 2004-06-10 WO disclosed
WO-2004045508-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO., INC. (US) 2004-06-03 WO disclosed
WO-2003018579-A1 ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-03-06 WO disclosed